Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

Published:2016-09-23 Issue:3 Volume:58 Page:722-725
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Maiti Abhishek¹²,Cortes Jorge E.²,Brown Yolanda D.²,Kantarjian Hagop M.²

Affiliation:

1. Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA;

2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

National Cancer Institute

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1207767

Reference15 articles.

1. Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

2. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

4. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.

5. Methylation of the ABL1 Promoter in Chronic Myelogenous Leukemia: Lack of Prognostic Significance

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic biomarkers;Epigenetics in Human Disease;2024

2. Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies;Current Hematologic Malignancy Reports;2022-10-19

3. Third-line therapy for chronic myeloid leukemia: current status and future directions;Journal of Hematology & Oncology;2021-03-18

4. Eradicating residual chronic myeloid leukaemia: basic research lost in translation;The Lancet Haematology;2021-02

5. Epigenetic Approaches to Cancer Therapy;Epigenetics in Human Disease;2018